CN113845472A - 可用于治疗癌症和糖尿病的6-芳基-4-吗啉-1-基吡啶酮化合物 - Google Patents
可用于治疗癌症和糖尿病的6-芳基-4-吗啉-1-基吡啶酮化合物 Download PDFInfo
- Publication number
- CN113845472A CN113845472A CN202111123598.XA CN202111123598A CN113845472A CN 113845472 A CN113845472 A CN 113845472A CN 202111123598 A CN202111123598 A CN 202111123598A CN 113845472 A CN113845472 A CN 113845472A
- Authority
- CN
- China
- Prior art keywords
- methyl
- phenyl
- pyridin
- mixture
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16156530 | 2016-02-19 | ||
EP16156530.4 | 2016-02-19 | ||
CN201780013738.3A CN108698996B (zh) | 2016-02-19 | 2017-02-17 | 可用于治疗癌症和糖尿病的6-芳基-4-吗啉-1-基吡啶酮化合物 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201780013738.3A Division CN108698996B (zh) | 2016-02-19 | 2017-02-17 | 可用于治疗癌症和糖尿病的6-芳基-4-吗啉-1-基吡啶酮化合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113845472A true CN113845472A (zh) | 2021-12-28 |
Family
ID=55404645
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201780013738.3A Active CN108698996B (zh) | 2016-02-19 | 2017-02-17 | 可用于治疗癌症和糖尿病的6-芳基-4-吗啉-1-基吡啶酮化合物 |
CN202111123598.XA Pending CN113845472A (zh) | 2016-02-19 | 2017-02-17 | 可用于治疗癌症和糖尿病的6-芳基-4-吗啉-1-基吡啶酮化合物 |
CN202111121825.5A Pending CN113754581A (zh) | 2016-02-19 | 2017-02-17 | 可用于治疗癌症和糖尿病的6-芳基-4-吗啉-1-基吡啶酮化合物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201780013738.3A Active CN108698996B (zh) | 2016-02-19 | 2017-02-17 | 可用于治疗癌症和糖尿病的6-芳基-4-吗啉-1-基吡啶酮化合物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111121825.5A Pending CN113754581A (zh) | 2016-02-19 | 2017-02-17 | 可用于治疗癌症和糖尿病的6-芳基-4-吗啉-1-基吡啶酮化合物 |
Country Status (19)
Country | Link |
---|---|
US (3) | US11077113B2 (fr) |
EP (1) | EP3416945B1 (fr) |
JP (3) | JP6997462B2 (fr) |
CN (3) | CN108698996B (fr) |
AU (3) | AU2017219846B2 (fr) |
CA (1) | CA3015045A1 (fr) |
CY (1) | CY1123285T1 (fr) |
DK (1) | DK3416945T3 (fr) |
ES (1) | ES2816376T3 (fr) |
HR (1) | HRP20201400T1 (fr) |
HU (1) | HUE050863T2 (fr) |
LT (1) | LT3416945T (fr) |
PL (1) | PL3416945T3 (fr) |
PT (1) | PT3416945T (fr) |
RS (1) | RS60898B1 (fr) |
RU (1) | RU2754664C2 (fr) |
SI (1) | SI3416945T1 (fr) |
TW (1) | TWI721104B (fr) |
WO (1) | WO2017140841A1 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6858984B2 (ja) * | 2016-02-19 | 2021-04-14 | スプリント バイオサイエンス アクティエボラーグ | がんおよび糖尿病の治療に有用な6−ヘテロシクリル−4−モルホリン−4−イルピリジン−2−オン化合物 |
LT3416945T (lt) * | 2016-02-19 | 2020-11-25 | Sprint Bioscience Ab | 6-aril-4-(morfolin-4-il)-1h-piridin-2-ono junginiai, tinkami vėžio ir diabeto gydymui |
CN116589462A (zh) | 2017-08-23 | 2023-08-15 | 思普瑞特生物科学公司 | 氮杂吲哚基吡啶酮化合物和二氮杂吲哚基吡啶酮化合物 |
JP7199737B2 (ja) * | 2017-08-23 | 2023-01-06 | スプリント バイオサイエンス アクティエボラーグ | ピリジルピリドン化合物 |
US11208423B2 (en) | 2017-08-23 | 2021-12-28 | Sprint Bioscience Ab | Pyridinamine-pyridone and pyrimidinamine- pyridone compounds |
CN116444510A (zh) * | 2017-08-23 | 2023-07-18 | 思普瑞特生物科学公司 | 吗啉基吡啶酮化合物 |
WO2020008046A1 (fr) | 2018-07-06 | 2020-01-09 | Sprint Bioscience Ab | Biomarqueur |
EP4251152A1 (fr) | 2020-11-25 | 2023-10-04 | Deciphera Pharmaceuticals, LLC | Dérivés de pyridylpyridone en tant qu'inhibiteurs de vps34 pour une utilisation dans le traitement d'une infection virale |
WO2022115549A1 (fr) | 2020-11-25 | 2022-06-02 | Deciphera Pharmaceuticals, Llc | Activité antivirale d'inhibiteurs de vps34 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130289031A1 (en) * | 2010-12-23 | 2013-10-31 | Sanofi | Pyrimidinone derivatives, preparation thereof and pharmaceutical use thereof |
US20130338159A1 (en) * | 2010-12-21 | 2013-12-19 | Novartis Ag | Bi-heteroaryl compounds as vps34 inhibitors |
WO2014145512A2 (fr) * | 2013-03-15 | 2014-09-18 | President And Fellows Of Harvard College | Inhibiteurs de l'autophagie à petites molécules, efficaces, et leurs procédés d'utilisation |
US20140275003A1 (en) * | 2013-03-14 | 2014-09-18 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
WO2015030057A1 (fr) * | 2013-08-29 | 2015-03-05 | 富士フイルム株式会社 | Nouveau dérivé de morpholine ou sel correspondant |
CN104603113A (zh) * | 2012-06-22 | 2015-05-06 | 赛诺菲 | 包含经取代吗啉的新型2,3-二氢-1H-咪唑并{1,2-a}嘧啶-5-酮和1,2,3,4-四氢嘧啶并{1,2-a}嘧啶-6-酮衍生物、其制备及其制药用途 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003295776B2 (en) | 2002-11-21 | 2011-05-12 | Novartis Vaccines And Diagnostics, Inc. | 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer |
GB2465405A (en) * | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
RU2561130C2 (ru) | 2009-07-02 | 2015-08-20 | Санофи | НОВЫЕ ПРОИЗВОДНЫЕ 1,2,3,4-ТЕТРАГИДРОПИРИМИДО{1,2-a}ПИРИМИДИН-6-ОНА, ИХ ПОЛУЧЕНИЕ И ФАРМАЦЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ |
GB201120317D0 (en) | 2011-11-24 | 2012-01-04 | Queen Mary & Westfield College | Screening method |
US10202373B2 (en) | 2014-01-14 | 2019-02-12 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
ES2908042T3 (es) | 2014-01-14 | 2022-04-27 | Takeda Pharmaceuticals Co | Heteroarilos y usos de los mismos |
MA39822A (fr) | 2014-04-03 | 2018-02-06 | Janssen Pharmaceutica Nv | Dérivés de pyrimidine bicycle |
MA39823A (fr) | 2014-04-03 | 2018-01-09 | Janssen Pharmaceutica Nv | Dérivés de pyridine macrocyclique |
KR20170048410A (ko) | 2014-09-17 | 2017-05-08 | 베르선 코포레이션 | 세린 프로테아제 저해제로서의 피라졸릴-치환된 피리돈 화합물 |
LT3416945T (lt) * | 2016-02-19 | 2020-11-25 | Sprint Bioscience Ab | 6-aril-4-(morfolin-4-il)-1h-piridin-2-ono junginiai, tinkami vėžio ir diabeto gydymui |
-
2017
- 2017-02-17 LT LTEP17705878.1T patent/LT3416945T/lt unknown
- 2017-02-17 CN CN201780013738.3A patent/CN108698996B/zh active Active
- 2017-02-17 JP JP2018562701A patent/JP6997462B2/ja active Active
- 2017-02-17 PT PT177058781T patent/PT3416945T/pt unknown
- 2017-02-17 ES ES17705878T patent/ES2816376T3/es active Active
- 2017-02-17 CA CA3015045A patent/CA3015045A1/fr active Pending
- 2017-02-17 CN CN202111123598.XA patent/CN113845472A/zh active Pending
- 2017-02-17 WO PCT/EP2017/053612 patent/WO2017140841A1/fr active Application Filing
- 2017-02-17 TW TW106105179A patent/TWI721104B/zh active
- 2017-02-17 SI SI201730395T patent/SI3416945T1/sl unknown
- 2017-02-17 EP EP17705878.1A patent/EP3416945B1/fr active Active
- 2017-02-17 RS RS20201057A patent/RS60898B1/sr unknown
- 2017-02-17 AU AU2017219846A patent/AU2017219846B2/en active Active
- 2017-02-17 HU HUE17705878A patent/HUE050863T2/hu unknown
- 2017-02-17 US US15/999,530 patent/US11077113B2/en active Active
- 2017-02-17 PL PL17705878T patent/PL3416945T3/pl unknown
- 2017-02-17 DK DK17705878.1T patent/DK3416945T3/da active
- 2017-02-17 CN CN202111121825.5A patent/CN113754581A/zh active Pending
- 2017-02-17 RU RU2018131775A patent/RU2754664C2/ru active
-
2020
- 2020-08-27 CY CY20201100804T patent/CY1123285T1/el unknown
- 2020-09-02 HR HRP20201400TT patent/HRP20201400T1/hr unknown
-
2021
- 2021-06-29 US US17/362,763 patent/US11633403B2/en active Active
- 2021-08-12 AU AU2021215234A patent/AU2021215234B2/en active Active
- 2021-12-08 JP JP2021199161A patent/JP7389504B2/ja active Active
-
2023
- 2023-03-09 US US18/181,046 patent/US20240050439A1/en active Pending
- 2023-10-13 AU AU2023248170A patent/AU2023248170A1/en active Pending
- 2023-11-10 JP JP2023192216A patent/JP2024016225A/ja active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130338159A1 (en) * | 2010-12-21 | 2013-12-19 | Novartis Ag | Bi-heteroaryl compounds as vps34 inhibitors |
US20130289031A1 (en) * | 2010-12-23 | 2013-10-31 | Sanofi | Pyrimidinone derivatives, preparation thereof and pharmaceutical use thereof |
CN104603113A (zh) * | 2012-06-22 | 2015-05-06 | 赛诺菲 | 包含经取代吗啉的新型2,3-二氢-1H-咪唑并{1,2-a}嘧啶-5-酮和1,2,3,4-四氢嘧啶并{1,2-a}嘧啶-6-酮衍生物、其制备及其制药用途 |
US20140275003A1 (en) * | 2013-03-14 | 2014-09-18 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
WO2014145512A2 (fr) * | 2013-03-15 | 2014-09-18 | President And Fellows Of Harvard College | Inhibiteurs de l'autophagie à petites molécules, efficaces, et leurs procédés d'utilisation |
WO2015030057A1 (fr) * | 2013-08-29 | 2015-03-05 | 富士フイルム株式会社 | Nouveau dérivé de morpholine ou sel correspondant |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108698996B (zh) | 可用于治疗癌症和糖尿病的6-芳基-4-吗啉-1-基吡啶酮化合物 | |
CN108884067B (zh) | 可用于治疗癌症和糖尿病的6-杂环基-4-吗啉-4-基吡啶-2-酮化合物 | |
CN111094271B (zh) | 吡啶胺-吡啶酮化合物和嘧啶胺-吡啶酮化合物 | |
CN111094244B (zh) | 吡啶基吡啶酮化合物 | |
ES2902346T3 (es) | Compuestos de azaindolilpiridona y diazaindolilpiridona | |
TWI803511B (zh) | 嗎啉基吡啶酮化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |